证券代码：688265 证券简称：南模生物 公告编号：2024-023 上海南方模式生物科技股份有限公司 2024 年 4 月，公司通过上海证券交易所交易系统以集中竞价交易方式回购公 司股份 250,001 股，占公司总股本 77,963,513 股的比例为 0.3207%，回购成交的最 高价为 27.38 元/股，最低价为 23.90 元/股，支付的资金总额为人民币 648.9317 万 元（不含税费、交易佣金等交易费用）。 重要内容提示： | 回购方案首次披露日 | 2024/2/24 | | --- | --- | | 回购方案实施期限 | 2024/2/23~2024/5/22 | | 预计回购金额 | 1,500 万元~3,000 万元 | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | √为维护公司价值及股东权益 | | 累计已回购股数 | 78.8912 万股 | | 累计已回购股数占总股本比例 | 1.0119% | | 累计已回购金额 | 2,145.3359 万元 | | 实际回购价格区间 | 23.90 元/股~29.98 元 ...

2024 年 4 月 上海南方模式生物科技股份有限公司 模式动物是实验动物的一个重要分支，能够模仿人类疾病的各个方面，帮助 科研人员获得有关疾病及其预防、诊断和治疗的资料，因此被广泛应用于生物分 析、表型分析以及药效分析与评价等领域。模式动物包括众多种类，如鼠类、猴 类、犬类等，其中小鼠的应用最为广泛。鼠类模型具有繁殖能力强、世代周期短； 组织器官结构和细胞功能结构与人类相似；与人类基因高度同源，且已完成全基 1 因组测序的优势，常应用于科学探索和药物开发，为应用最广泛的模式动物。基 因修饰动物指利用各种基因编辑技术把模式动物中目的 DNA 片段导入或删除， 实现内源基因的修改，从而构造出能够模拟人类特定生理、病理、细胞特征的生 物模型，多用于靶点研究与药效评估。相较其他类别动物模型，基因修饰动物模 型可以实现对人类生理或病理更精确的模拟，更适合作为研究人类基因功能和疾 病致病机制探索的实验模型；当前大量学术研究、药物开发围绕靶点进行，基因 修饰动物契合了这一研发潮流。 南模生物成立于 2000 年，作为国内较早从事基因修饰动物模型业务的公司 之一，深耕基因修饰动物模型市场多年，始终以研发创新为驱动，核心技术 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 25% year-over-year growth [200]. - The company's operating revenue for 2023 reached ¥366,548,781.43, representing a year-on-year increase of 20.99% compared to ¥302,965,239.57 in 2022 [23]. - The net profit attributable to shareholders of the listed company was -¥20,582,607.05, a decline of 281.18% from -¥5,399,643.49 in the previous year [26]. - The net profit attributable to the parent company was approximately -20.58 million yuan, a year-on-year decline of 281.18% [37]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was approximately -39.51 million yuan, a year-on-year decrease of 33.67% [37]. - The gross margin improved to 60%, up from 55% in the previous year, indicating better cost management [15]. - The company's total assets at the end of 2023 were ¥1,997,768,441.18, down 2.72% from ¥2,053,677,965.52 in 2022 [23]. - The company's total production capacity at the end of the reporting period was approximately 140,000 cage positions, with a year-on-year optimization in cage utilization rates across various bases [42]. Research and Development - The company is investing $10 million in R&D for new therapeutic solutions aimed at rare diseases [15]. - Research and development expenses accounted for 21.89% of operating revenue, an increase of 0.19 percentage points from 21.70% in 2022 [25]. - The total R&D expenditure for the year was approximately ¥80.24 million, an increase of 22.02% compared to the previous year, with R&D expenses accounting for 21.89% of total revenue [95]. - The company has developed over 18,000 models, with more than 11,000 standardized models and provided over 7,500 customized models to clients [38]. - The company is focusing on continuous R&D of gene editing technology and gene-modified animal models, leveraging advanced technology and services in the life sciences and biomedicine sectors [59]. - The company has established a comprehensive drug efficacy evaluation service using genetically modified animal models, covering major human diseases [107]. - The company aims to enhance gene editing technology to improve target gene editing success rates and reduce off-target risks [176]. Market Expansion and Strategy - The company is expanding its market presence in Europe, targeting a 15% market share by the end of the next fiscal year [15]. - The company plans to expand its overseas business development team, particularly in biopharmaceutical hubs like Boston and California, to enhance market penetration [46]. - The company is committed to deepening domestic market penetration while expanding its global presence, particularly in Europe and the United States [182]. - The company is exploring partnerships with key industry players to enhance distribution channels and expand reach [199]. - The company plans to enhance its digital platform, aiming for a 40% increase in user engagement metrics [15]. - The company is expanding its marketing network by enhancing collaboration among sales, business, and technical support departments, and increasing brand exposure through events and new media operations [188]. Governance and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants [6]. - The company has confirmed that all board members attended the board meeting, ensuring governance compliance [6]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties [8]. - The company has not experienced any violations of decision-making procedures regarding external guarantees [8]. - The company has not disclosed any special arrangements for corporate governance [8]. Risks and Challenges - The company has outlined potential risks in its operations, which are detailed in the "Management Discussion and Analysis" section of the report [5]. - The company emphasizes the importance of understanding the risks associated with forward-looking statements regarding future plans and strategies [7]. - The company faced increased production costs due to new facilities and rising expenses, impacting profitability [26]. - The company is exposed to competition from both domestic and international firms in the genetically modified animal model industry, which could impact its market expansion efforts [118]. - The company may face risks related to regulatory compliance as the industry is subject to increasing scrutiny regarding animal welfare and ethical standards [127]. Investments and Acquisitions - A strategic acquisition of a smaller biotech firm was completed, which is anticipated to add $50 million in annual revenue [15]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of $100 million allocated for this purpose [200]. - The company has made private equity investments totaling 11,500,000 RMB, with a reported loss of 152.48 RMB during the period [169]. Customer and Sales Performance - User data showed an increase in active users, reaching 1.2 million, which is a 30% increase compared to the previous year [15]. - The company signed new orders worth 377 million yuan during the reporting period, reflecting a growth rate of 13.55% [49]. - The company has established sales in nearly 20 countries, including the United States, Germany, Japan, South Korea, and the United Kingdom [46]. - Customized model revenue increased by 64.75% year-on-year, while standardized model revenue grew by 34.03% [48]. Future Outlook - The company provided guidance for the next fiscal year, projecting revenue growth of 20% to $600 million [15]. - The company aims to enhance investment and financing efficiency, broadening external financing channels and improving the efficiency of raised funds to support sustainable and high-quality development [183]. - The company aims to become a leader in the genetically modified model organism industry, contributing to advancements in biomedicine and improving human health [177].

Financial Performance - The company's operating revenue for Q1 2024 was ¥82,932,302.56, representing a decrease of 5.01% compared to the same period last year[4] - Total operating revenue for Q1 2024 was ¥82,932,302.56, a decrease of 5.3% compared to ¥87,304,768.91 in Q1 2023[18] - The net profit attributable to shareholders was -¥12,897,060.70, with a net profit excluding non-recurring items of -¥18,517,804.80[4] - Net loss for Q1 2024 was ¥12,897,060.70, an improvement from a net loss of ¥14,231,619.55 in Q1 2023, indicating a 9.4% reduction in losses[19] - The company's total assets decreased to ¥1,953,324,217.74 in Q1 2024 from ¥1,997,768,441.18 in Q1 2023, a decline of 2.2%[17] - Total liabilities decreased to ¥244,050,810.79 in Q1 2024 from ¥260,985,055.13 in Q1 2023, representing a reduction of 6.5%[17] - The company's total equity attributable to shareholders decreased to ¥1,709,273,406.95 in Q1 2024 from ¥1,736,783,386.05 in Q1 2023, a decline of 1.6%[17] - The basic and diluted earnings per share for Q1 2024 were both -¥0.17, compared to -¥0.18 in Q1 2023, reflecting a slight improvement[19] Cash Flow - The net cash flow from operating activities was -¥28,394,359.82, indicating a significant cash outflow[4] - In Q1 2024, the company's cash inflow from operating activities was CNY 67,757,018.71, compared to CNY 66,448,951.40 in Q1 2023, reflecting a slight increase of 1.96%[22] - The net cash outflow from operating activities improved to CNY -28,394,359.82 in Q1 2024 from CNY -33,872,953.18 in Q1 2023, indicating a reduction in losses by approximately 16.5%[22] - Cash inflow from investment activities totaled CNY 296,496,310.15 in Q1 2024, down from CNY 885,839,718.79 in Q1 2023, representing a decrease of 66.5%[23] - The net cash flow from investment activities was CNY 60,121,373.98 in Q1 2024, compared to CNY 31,629,037.84 in Q1 2023, showing an increase of 90.2%[23] - The company reported a cash outflow from financing activities of CNY 20,983,339.83 in Q1 2024, significantly higher than CNY 6,364,701.52 in Q1 2023, marking an increase of 229.5%[23] - The net increase in cash and cash equivalents for Q1 2024 was CNY 10,740,267.10, contrasting with a decrease of CNY -8,743,172.73 in Q1 2023[23] - The ending balance of cash and cash equivalents rose to CNY 108,343,188.50 in Q1 2024 from CNY 358,699,458.77 in Q1 2023, indicating a decrease of 69.8% year-over-year[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,953,324,217.74, down 2.22% from the end of the previous year[5] - The total current assets as of March 31, 2024, amounted to ¥108,343,188.50, an increase from ¥97,602,921.40 as of December 31, 2023, reflecting a growth of approximately 10.8%[15] - The trading financial assets decreased to ¥866,319,453.74 from ¥927,284,641.17, representing a decline of about 6.6%[15] - Accounts receivable increased to ¥128,010,514.23 from ¥108,035,604.85, indicating a rise of approximately 18.5%[15] - Inventory rose to ¥16,853,575.55 compared to ¥15,828,142.53, showing an increase of about 6.4%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,753[9] - The top shareholder, Shanghai Dish Enterprises Management Consulting Co., Ltd., holds 27,771,000 shares, representing 35.62% of total shares[9] - The number of shares held by the top 10 shareholders includes Shanghai Technology Venture Capital Co., Ltd. with 10,576,333 shares, representing 13.57% of total shares[13] - Shanghai Pudong New Emerging Industry Investment Co., Ltd. holds 2,160,000 shares, accounting for 2.77% of total shares[13] - The company has not reported any significant changes in the shareholder structure due to margin trading activities[13] - The total number of shares repurchased by the company as of the report date is 990,229 shares[11] Research and Development - Research and development expenses totaled ¥19,334,427.95, accounting for 23.31% of operating revenue, an increase of 0.63 percentage points year-on-year[5] - Research and development expenses for Q1 2024 were ¥19,334,427.95, slightly down from ¥19,799,024.04 in Q1 2023, showing a decrease of 2.3%[18] - The company has not disclosed any new product developments or technological advancements in this quarter[15] Mergers and Acquisitions - There are no significant mergers or acquisitions reported during this period[15] Audit Information - The company did not conduct an audit for the Q1 financial statements[4] Profitability - The company reported non-recurring gains of ¥5,620,744.10 for the period, primarily from government subsidies and financial asset valuations[6][7] - The company reported a gross profit margin of approximately 43.4% for Q1 2024, compared to 40.0% in Q1 2023, indicating an improvement in profitability[18] - The weighted average return on net assets was -0.75%, an increase of 0.07 percentage points[5]

证券代码：688265 证券简称：南模生物 公告编号：2024-011 上海南方模式生物科技股份有限公司 关于以集中竞价交易方式回购股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海南方模式生物科技股份有限公司（以下简称"公司"）截至 2024 年 3 月 31 日，通过上海证券交易所交易系统以集中竞价交易方式回购公司股份 538,911 股，占公司总股本 77,963,513 股的比例为 0.6912%，回购成交的最 高价为 29.98 元/股，最低价为 26.03 元/股，支付的资金总额为人民币 1,496.4042 万元（不含税费、交易佣金等交易费用）。 2024 年 3 月，公司通过上海证券交易所交易系统以集中竞价交易方式回购 公司股份 509,654 股，占公司总股本 77,963,513 股的比例为 0.6537%，回购成交 的最高价为 29.98 元/股，最低价为 26.03 元/股，支付的资金总额为人民币 1,416.7307 万元（不含税费、交易佣金等交易费用）。 截至 ...

证券代码：688265 证券简称：南模生物 公告编号：2024-010 上海南方模式生物科技股份有限公司 关于以集中竞价交易方式回购公司股份 达到总股本 1%暨回购股份进展的公告 价格不超过 50 元/股（含），回购期限自董事会审议通过本次回购方案之日起 12 个月内。 具体内容详见公司于 2023 年 8 月 31 日及 2023 年 9 月 28 日在上交所网站 （www.sse.com.cn）披露的《关于以集中竞价交易方式回购股份方案的公告》 （公告编号：2023-029）和《关于以集中竞价交易方式回购股份的回购报告书》 （公告编号：2023-032）。 （二）第二期回购方案 公司于 2024年 2月 23日召开第三届董事会第十二次会议，公司全体董事出 席会议，以全票同意的表决结果审议通过了《关于以集中竞价交易方式回购股 份方案的议案》。同意公司使用自有资金以集中竞价交易方式回购公司股份， 用于维护公司价值及股东权益，回购资金总额不低于人民币 1,500万元（含）， 不超过人民币 3,000 万元（含），回购价格不超过 43 元/股（含），回购期限自 董事会审议通过本次回购方案之日起 3 个月内。 具体 ...

证券代码：688265 证券简称：南模生物 上海南方模式生物科技股份有限公司 投资者关系活动记录表 编号：2024-002 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 □新闻发布会 □路演活动 活动类别 现场参观 □其他 参与单位名称 惠通基金、华鑫证券、中原证券 时间 2024年2月1日 地点 公司会议室 上市公司接待 董事会秘书 刘 雯 人员姓名 一、简要介绍公司 2023年年度业绩预告情况 公司于2024年1月31日披露了《2023年年度业绩 预告》，预计 2023 年年度实现营业收入 36,000.00 万元 到38,000.00 万元，同比变动比率为 18.83%到 25.43%； 归属于母公司所有者的净利润为-2,400.00 万元到 ...

证券代码：688265 证券简称：南模生物 公告编号：2024-009 上海南方模式生物科技股份有限公司 关于以集中竞价交易方式首次回购公司股份 暨回购股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海南方模式生物科技股份有限公司（以下简称"公司"）2024 年 2 月 29 日 通过上海证券交易所交易系统以集中竞价交易方式首次回购公司股份 29,257 股，占公司总股本 77,963,513 股的比例为 0.0375%，回购成交的最高 价为 27.72 元/股，最低价为 26.95 元/股，支付的资金总额为人民币 796,734.92 元（不含税费、交易佣金等交易费用）。 2024 年 2 月 29 日，公司通过上海证券交易所交易系统以集中竞价交易方式 首次回购公司股份 29,257 股，占公司总股本 77,963,513 股的比例为 0.0375%， 回购成交的最高价为 27.72 元/股，最低价为 26.95 元/股，支付的资金总额为人 民币 796,734.92 元（不含税费、交易 ...

上海南方模式生物科技股份有限公司 关于回购股份事项前十名股东和前十名无限售条件股东 持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688265 证券简称：南模生物 公告编号：2024-008 一、公司前十名股东持股情况 | 10 | 三希（北京）资产管理有限公司－三希赤霄一 | 708,500 | 0.91 | | --- | --- | --- | --- | | | 号私募证券投资基金 | | | 二、公司前十名无限售条件股东持股情况 | 序号 | 持有人名称 | 总持有数量 （股） | 占无限售条件 流通股比例 | | --- | --- | --- | --- | | | | | （%） | | 1 | 上海科技创业投资有限公司 | 10,639,333 | 21.54 | | 2 | 深圳前海海润荣丰投资合伙企业（有限合伙） | 6,716,352 | 13.60 | | 3 | 康君投资管理（北京）有限公司－北京康君宁 | 5,234,977 | 10.60 | | | 元股权投资合 ...

1、审议通过《关于以集中竞价交易方式回购股份方案的议案》 为维护公司价值和广大投资者权益，促进公司可持续健康发展，基于对公司 未来发展前景的信心和对公司价值的认可，公司综合考虑目前经营情况、财务状 况、未来盈利能力等因素，董事会同意公司以不超过人民币43元/股（含）的价格， 用自有资金回购资金总额不低于人民币1,500万元（含）不超过人民币3,000万元 （含）的股份，用于维护公司价值及股东权益，回购期限为自董事会审议通过本 次股份回购方案之日起不超过3个月。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海南方模式生物科技股份有限公司（以下简称"公司"）第三届董事会第十 二次会议于 2024 年 2 月 23 日以现场结合通讯方式召开。本次会议的通知已于 2024 年 2 月 20 日以电子邮件方式送达全体董事。本次会议由董事长费俭先生召 集并主持，应参会董事 9 人，实际出席董事 9 人，其中独立董事 3 人，公司监 事、高级管理人员列席了会议。本次会议的召集、召开符合《中华人民共和国公 司 ...